up home page bottom

French German version Spanish version Italian version

header image

Adventures of Merck’s HPV Vaccine Lobby

The Gardasil issues I researched were the relatively limited trial period, the sketchy trail data; the cost benefit of a drug that was design to prevent a cancer that has been declining in both incidence and mortality for over 40-years. Cervical cancer is easily detected by regular PAP screening and in the early stages, the most treatable cancer. The other aspect of Gardasil roll-up that didn’t pass the smell test was the Merck Marauder School of lobbying today for a more profitable tomorrow. Merck literally carpet-bombed the halls of power and influence with cash to get GARDASIL approved by the FDA (while holding up the Glaxo HPV-vaccine, Cervarix), they got Gardasil endorsed by the CDC and mandated in many states as yet another vaccine necessary to attend school, and managed to get state legislators to pass bills to force insurance companies to pay for the Gardasil shot. As I researched the payouts and pay offs of state, local and federal representatives, I asked when did safety go on sale? Then I found out about Merck paying doctors to go on the stump to endorse Gardasil. Some docs with great speaking skills picked up several hundred thousand dollars in a year. Then there was the scandal about “Medical Journal-Like’ publications written by ‘bought and paid for’ doctors who dutifully regurgitated the WORD according to Merck.

Share

Glaxo Gearing Up To Compete with Merck’s Gardasil In US Market

The FDA’s approval for the ‘other’ HPV-vaccine, Cervarix is still delayed. GlaxoSmithKline, the world’s second-largest drugmaker, requested a ‘priority’ review, potentially prompting an approval decision and sale of the Cervarix vaccine by the end of 2007, said James Tursi, Glaxo’s director of medical affairs for cervical cancer vaccines, at a medical meeting in San Diego.

Share
Private